Biotage Overview
- Founded
-
1997
- Status
-
Public
- Employees
-
516
- Stock Symbol
-
BIOT
- Investments
-
9
- Share Price
-
$13.97
- (As of Friday Closing)
Biotage General Information
Description
Biotage AB provides separation technology and solutions for analytical and organic chemistry from research to commercial analytical laboratories and industrial applications. Its customers span a broad range of market segments including pharmaceutical, biotech, diagnostic, contract research, and contract manufacturers as well as clinical, forensic, and academic laboratories in addition to organizations focused on food safety, clean water, and environmental sustainability. It serves three geographic markets: The Americas, APAC (Asia-Pacific,) and EMEA (Europe, Middle East & Africa). The company's product areas include Small Molecules & Synthetic Therapeutics, Biologics & Advanced Therapeutics, Scale-Up, Diagnostics, Analytical Testing, and Water & Environmental Testing.
Contact Information
- Box 8
- 751 03 Uppsala
- Sweden
Biotage Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $13.97 | $13.39 | $11.00 - $22.13 | $883M | 66M | 198K | $0.35 |
Biotage Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 |
|---|---|---|---|---|
| EV | 829,409 | 1,157,125 | 1,881,789 | 1,094,591 |
| Revenue | 147,944 | 154,364 | 143,458 | 118,435 |
| EBITDA | 39,720 | 44,555 | 40,289 | 32,537 |
| Net Income | 22,930 | 26,417 | 23,871 | 18,980 |
| Total Assets | 227,937 | 224,218 | 220,115 | 174,812 |
| Total Debt | 21,134 | 20,802 | 22,431 | 19,749 |
Biotage Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biotage Comparisons
Industry
Financing
Details
000000
000000
Biotage Competitors (8)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Agilent Technologies | Corporation | Santa Clara, CA | 00000 | 00.000 | 0000 | 00.000 |
| 0000000 0000000000 | Private Equity-Backed | Vernon Hills, IL | 000 | 00.00 | 000000000 | 00.00 |
| 0000000 00000 0000 | Formerly PE-Backed | Wilmington, MA | 00000 | 00000 | 00000000000 | 00000 |
| 00000 00000 | Corporation | Basel, Switzerland | 00000 | 00000 | 00000000000 | 00000 |
| 0000000 0000000000 | Formerly PE-Backed | Holliston, MA | 000 | 0000 | 000000 - 000 | 0000 |
Biotage Patents
Biotage Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| EP-4162998-A1 | Evaporator | Pending | 08-Oct-2021 | 000000000 | 0 |
| JP-2023514433-A | Large capacity separation system | Pending | 24-Feb-2020 | 00000000000 | |
| AU-2021225321-A1 | Large volume separation system | Pending | 24-Feb-2020 | 00000000000 | |
| CA-3165487-A1 | Large volume separation system | Pending | 24-Feb-2020 | 00000000000 | |
| EP-3869207-A1 | Large volume separation system | Pending | 24-Feb-2020 | G01N35/1016 | 0 |
Biotage Executive Team (8)
Biotage Board Members (11)
| Name | Representing | Role | Since |
|---|---|---|---|
| Anders Walldov | Self | Board Member | 000 0000 |
| Asa Hedin | Self | Board Member | 000 0000 |
| Karolina Lawitz | Self | Board Member | 000 0000 |
| Mark Bradley | Biotage | Board Member | 000 0000 |
| Nils Granlund | Self | Board Member | 000 0000 |
Biotage Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Biotage Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Biotage Investments & Acquisitions (9)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000 000000 | 01-Jun-2023 | 0000000000 | 00000 | Drug Discovery | 00000 000 |
| 000000 | 20-Oct-2021 | 0000000000 | 000.00 | Industrial Chemicals | 00000 000 |
| 00000000 | 15-Jan-2019 | 0000000000 | 000.00 | Electronic Equipment and Instruments | 000000 0ø |
| 0000000 00000 | 16-Jan-2018 | 0000000000 | 000.00 | Distributors/Wholesale | 000000 0ø |
| Chreto | 31-Aug-2016 | Corporate | 00.000 | Biotechnology | 000000 0ø |
Biotage Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| ATDBio | Industrial Chemicals | Southampton, United Kingdom | 2005 |
| 000000 00000000000 | Drug Discovery | Cambridge, United Kingdom | 0000 |
Biotage ESG
Risk Overview
Risk Rating
Updated February, 27, 2023
19.32 | Low Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
00.00
Management
Management is related to actions taken to manage ESG issues
00.00
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
00 of 15,233
Rank
Percentile
Pharmaceuticals
Industry
00 of 866
Rank
Percentile
Laboratory Equipment and Services
Subindustry
00 of 64
Rank
Percentile
